Changing the way cancer drugs are priced in the U.S. is apparently even harder than it sounds.
EQRx, a company founded to upend the costly U.S. system for pricing new drugs, said Thursday it would abandon that goal for the two products that are closest to the market.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
